# OnCo record tropion-breast03 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/tropion-breast03/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "tropion-breast03", "NCT05629585" ;
  schema:name "TROPION-Breast03"@en ;
  schema:description "TROPION-Breast03 is the Dato-DXd counterpart to ASCENT-05: an ADC, with or without immunotherapy, for triple-negative patients with leftover cancer at surgery."@en ;
  schema:url <https://onco.cc/trials/tropion-breast03/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05629585>, <https://journals.sagepub.com/doi/10.1177/17588359241248336>, <https://doi.org/10.1177/17588359241248336> ;
  onco:status "active" ;
  onco:phase "3" ;
  schema:startDate "2022-11-28" ;
  onco:related <https://onco.cc/ideas/idea-post-neoadjuvant-adc/>, <https://onco.cc/trials/ascent-05/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/keynote-522/> .